Redhill antibiotic talicia is approved by FDA for the treatment of adult Helicobacter pylori infection

On November 18, 2019, the arterial network (micro signal: vcpeat) learned from the external media information that red hill biopharma (Redhill), a biopharma company, announced that its antibiotic talicia had been approved by the FDA for use in the treatment of adult patients infected with Helicobacter pylori, so as to reduce the risk of gastric cancer caused by Helicobacter pylori and solve the problem of antibiotic resistance of the bacteria After talicia's approval, Redhill's shares rose more than 13% on the Tel Aviv Stock Exchange In addition, the company also received $59 million in strategic investment led by cosmopharmaceuticals Talicia is the first FDA approved three in one oral capsule based on the antibiotic rifabutin Redhill released the results of talicia's phase III validation test in December 2018, which showed that the eradication rate of the drug to H pylori was as high as 84%, and the bacteria did not show resistance This achievement will bring good news to patients with gastric cancer It is understood that more than 50% of the world's population has been infected with H pylori This kind of bacteria transmitted through feces often parasitize in gastric mucus or gastric mucosa cells with low gastric acid, which is easy to induce gastritis or even gastric cancer Due to the abuse of antibiotics, 25% to 40% of infected patients can not eradicate gastrointestinal diseases Now, the biological drug talicia of Redhill is expected to provide new treatment options Redhill, founded in 2009, is a biopharmaceutical company with a leading position in the market of patented drugs The company has an experienced management team based in Tel Aviv, Israel, and has a commercial operation headquarters in North Carolina In addition to talicia, Redhill will continue to develop new gastric disease treatment drugs to meet the medical needs of patients In recent years, bacterial resistance to antibiotics has become a long-standing problem that can not be ignored According to the study published in clinical gastroenterology and hepatology in 2015, in a clinical research project based on 656 male veterans' samples, the drug resistance of Helicobacter pylori to clarithromycin increased significantly in five years "Helicobacter pylori is the main cause of peptic ulcer and gastritis," said Dr Colin Howden, director of the center for Health Sciences, Department of Gastroenterology, University of Tennessee Due to the increase of bacterial resistance and the lack of effective treatment options in the past decade, the treatment of Helicobacter pylori infectious diseases is becoming more and more serious Due to the relatively low price of antibiotics and the high requirements of preservation conditions, many biopharmaceutical companies lack of development motivation, and the creation of new antibiotics faces double challenges in science and economy As many as 2 million HP patients need to be treated each year in the United States, Redhill will continue to develop innovative drugs for such diseases and expand the sales market of its products Penicillin is the reprinted content of yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.